North Dakota State Investment Board Buys New Shares in Edwards Lifesciences Corporation $EW

North Dakota State Investment Board bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 19,728 shares of the medical research company’s stock, valued at approximately $1,682,000.

Several other hedge funds and other institutional investors have also made changes to their positions in EW. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at $25,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $28,000. Dorato Capital Management acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $29,000. N.E.W. Advisory Services LLC lifted its holdings in Edwards Lifesciences by 533.9% during the 4th quarter. N.E.W. Advisory Services LLC now owns 374 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 315 shares during the last quarter. Finally, Rakuten Securities Inc. lifted its holdings in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on EW shares. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. BTIG Research raised their price target on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a report on Friday, April 24th. UBS Group reaffirmed a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Finally, Robert W. Baird upped their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.65.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 24,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the transaction, the vice president owned 21,266 shares of the company’s stock, valued at $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 106,684 shares of company stock valued at $8,811,739 over the last quarter. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Down 0.3%

Shares of Edwards Lifesciences stock opened at $82.13 on Wednesday. The firm has a 50-day moving average of $81.48 and a 200-day moving average of $82.87. The stock has a market cap of $47.29 billion, a PE ratio of 43.69, a PEG ratio of 2.07 and a beta of 0.87. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.